CentreForMedicalHumanities.org Editorial Team | April 27, 2026 | Affiliate Disclosure: This article contains affiliate links. A commission may be earned if a purchase is made through links in this article at no additional cost to the reader.
These statements have not been evaluated by the Food and Drug Administration. Supplements are not intended to diagnose, treat, cure, or prevent any disease. This article is for informational and educational purposes only and does not constitute medical advice.
Nerve Pain Not Getting Better: What to Do Next
Roughly 50% of people on first-line neuropathic pain treatments — gabapentin, pregabalin, tricyclics, SNRIs — don't achieve adequate relief from any single agent, according to a Cochrane review of the clinical evidence. That's not a failure of any one drug. It reflects how heterogeneous neuropathic pain actually is: different root causes, different nerve fiber types affected, different bodies responding differently to the same mechanism.
If you're in that 50%, the answer isn't to try more of the same thing harder. There are specific, documented reasons why both pharmaceutical and supplement approaches underperform — and identifying which one applies to your situation changes what you do next.
A Verifiable Starting Point: How Difficult Neuropathic Pain Actually Is to Treat
Neuropathic pain affects an estimated 7–10% of the global population, according to multiple epidemiological reviews in journals including Pain and The Lancet. What's less discussed outside specialist settings is that even gold-standard pharmaceutical treatments — tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, gabapentin, and pregabalin — produce “much improvement” or “complete relief” in only a minority of treated patients. A Cochrane review of first-line neuropathic pain treatments found roughly 50% of people don't achieve adequate pain relief from any single first-line agent. That's not a failure of any one drug — it's a statement about how heterogeneous neuropathic pain is as a condition.
The reason isn't that the drugs don't work. It's that neuropathic pain isn't one thing. It's a category of experience produced by dozens of different underlying causes, affecting different nerve types, driven by different molecular mechanisms, in bodies with different comorbidities and medication profiles. A treatment approach calibrated to one person's cause may be completely wrong for another person's — even when the surface-level symptoms look identical.
Why Does Gabapentin Stop Working for Nerve Pain?
Gabapentin (and its more potent cousin, pregabalin) works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters and dampening central sensitization — the state in which the nervous system itself becomes hyperreactive to input. It's not a cure; it's a modulator.
When people describe gabapentin “stopping working,” what's usually happening is one of several specific scenarios. The underlying cause is progressing — gabapentin was effective at the previous level of nerve dysfunction, but the progressive nerve damage (from uncontrolled glucose, ongoing inflammation, continued alcohol use, or other drivers) has outpaced the dose. Alternatively, the dose prescribed was never in the therapeutic range for neuropathic pain in the first place — gabapentin requires careful titration from low starting doses to the therapeutic range (often 900–3600 mg/day for neuropathic pain in published protocols), and underdosing in primary care settings is well-documented. Or the side effect burden — sedation, cognitive fog, weight gain, mood effects — has become incompatible with quality of life at the dose required for meaningful pain control.
None of these are reasons to stop gabapentin without a physician conversation. But understanding which scenario applies shapes the next discussion with a prescriber.
Why Don't Neuropathy Supplements Work for Most People?
The supplement failure picture has a different architecture. Most people who try a nerve support supplement and don't notice meaningful improvement fall into one of these categories:
The underlying cause hasn't been addressed. A B-complex supplement does not resolve B12 deficiency if the problem isn't dietary intake but absorption — which is the more common issue in adults over 50, where declining stomach acid impairs absorption of food-bound B12. Oral B12 at doses high enough to bypass the intrinsic factor-dependent absorption pathway (1,000 mcg or more daily) or sublingual or injectable B12 may be needed. Similarly, a botanical nerve formula does not address the glucose dysregulation driving diabetic neuropathy. The supplement works alongside an addressed root cause, not instead of it.
The formula's ingredients don't match the specific mechanism. Someone whose nerve symptoms are primarily driven by oxidative stress damage will respond differently to an antioxidant-focused supplement than someone whose primary driver is B-vitamin deficiency or systemic inflammation. A purely botanical formula like NeuroSalt — which operates through neural calming, antioxidant protection, and dopamine-pathway pain modulation — is not the same intervention as a B-vitamin-forward formula, and neither is the same as alpha-lipoic acid. For a direct comparison of how botanical approaches differ mechanistically from the most-studied neuropathy nutrients, see NeuroSalt vs alpha-lipoic acid vs benfotiamine 2026: how the formulas differ.
Timeline expectations are calibrated to pharmaceutical speed. Botanical formulas modulate physiological processes over weeks — they don't block pain receptors acutely the way gabapentin does. Corydalis, the best-studied ingredient in NeuroSalt for pain-specific applications, was evaluated across 3–4 week timeframes in published research. Expecting meaningful nerve comfort changes in 5–7 days from any botanical formula is not consistent with how these compounds work. Four to eight weeks of consistent daily use is a more appropriate evaluation window.
The lifestyle drivers are still active. This is the failure point that gets the least attention. Any supplement — botanical or otherwise — is an adjunct. If sleep is severely disrupted, cortisol is chronically elevated, physical activity is minimal, and dietary micronutrient intake is poor, these factors collectively set a baseline level of inflammatory activity and pain sensitization that supplements moderate at the margin. The ceiling effect is real: supplements can help within the context of other factors, but they can't override them.
A Practical Framework: What to Do When Nerve Pain Isn't Improving
This is a step-by-step approach, not a single answer — because the right next step depends on which part of the picture hasn't been addressed yet.
Step 1: Confirm the diagnosis is established. Has peripheral neuropathy been formally evaluated by a physician? Has bloodwork been done to identify or rule out the treatable causes — B12 status, thyroid function, fasting glucose and HbA1c, complete metabolic panel? If not, this comes first. Treating undiagnosed B12 deficiency with a botanical supplement is like patching a roof through a window — it misses the actual opening.
Step 2: Assess whether current pharmaceutical management is at therapeutic dose. If you're on gabapentin, pregabalin, or a tricyclic for neuropathic pain and the pain isn't controlled, the question for your prescriber isn't “should I try a supplement” — it's “is this dose optimized?” If the dose is limited by side effects, a different drug class (duloxetine, nortriptyline) or a combination approach may be the clinical conversation to have.
Step 3: Audit the lifestyle variables directly. Sleep: are you getting 7–9 hours and waking reasonably refreshed? If not, sleep architecture is a direct therapeutic target, not a background issue. Stress: is your cortisol regulation being actively addressed — through whatever combination of exercise, sleep, stress reduction practices, or if indicated, clinical mental health support? Body composition: is metabolic inflammation being actively managed? These are the primary levers. They don't have pharmaceutical solutions — they have lifestyle solutions.
Step 4: Evaluate whether a botanical adjunct makes sense. If the root cause is addressed, the pharmaceutical regimen is optimized or clinically appropriate, and lifestyle factors are being managed — a botanical nerve support formula may offer additional value through its specific mechanisms. The calming and antioxidant pathways in formulas like NeuroSalt address dimensions of neuropathic discomfort that pharmaceuticals don't specifically target. That complementary positioning is where the legitimate clinical conversation lives. For a full ingredient-by-ingredient look at NeuroSalt's formula and what the research says, see NeuroSalt 2026: ingredients, pink salt trick, is it legit?. For safety considerations before adding a botanical formula to a medication regimen, see NeuroSalt safety and drug interactions: what to review before starting.
Step 5: Know when none of these is right. If nerve symptoms are progressive, worsening despite optimized treatment across all of the above, or affecting motor function — referral to a neurologist or a multidisciplinary pain clinic is the next step, not another supplement. Neuropathic pain at that severity is a clinical management problem that benefits from specialist coordination, including potentially nerve blocks, TENS therapy, or evaluation for underlying conditions not yet identified.
The Honest Picture on Supplement Categories for Nerve Pain
There is meaningful published research supporting several specific supplement categories for neuropathy. Alpha-lipoic acid at high doses (600–1,800 mg daily) has the most substantial clinical trial data for diabetic peripheral neuropathy specifically, with multiple randomized controlled trials showing symptom reduction over 3–5 week periods. Benfotiamine — the fat-soluble form of thiamine that crosses nerve cell membranes more effectively than standard B1 — has controlled trial evidence for diabetic neuropathy with a well-understood mechanism. High-dose methylcobalamin (B12) has RCT data for symptom improvement in established B12-deficiency neuropathy. These represent the evidence-based standard of care within the supplement category.
Botanical formulas like NeuroSalt operate through different mechanisms — neural calming, dopamine-pathway pain modulation via Corydalis, antioxidant protection via prickly pear — and the research base at the ingredient level is legitimate, though less extensive than ALA or benfotiamine for diabetic neuropathy specifically. That's not a disqualifier. It's context for making a more informed choice about which formula's mechanism aligns with your specific situation. Both categories have a legitimate place — in different people, for different reasons, at different stages of their nerve health picture.
These statements have not been evaluated by the Food and Drug Administration. Supplements are not intended to diagnose, treat, cure, or prevent any disease. This article is for informational and educational purposes only and does not constitute medical advice. If nerve symptoms are worsening or progressive, consult a licensed healthcare professional promptly.